Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AMINOPHYLLINE DYE FREE vs ACCURBRON
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Aminophylline is a salt form of theophylline that exerts bronchodilation by inhibiting phosphodiesterase, increasing intracellular c AMP. It also blocks adenosine receptors, stimulates central respiratory drive, and reduces diaphragmatic fatigue.
Ipratropium bromide is an anticholinergic agent that inhibits muscarinic acetylcholine receptors (M1-M3), reducing vagal tone and bronchoconstriction. Albuterol is a beta2-adrenergic agonist that stimulates adenylate cyclase, increasing c AMP and causing bronchodilation.
Treatment of bronchospasm associated with asthma, chronic bronchitis, emphysema, and COPD,Apnea of prematurity (off-label)
FDA-approved: Treatment of COPD exacerbations,Off-label: Acute asthma exacerbations
Loading dose: 6 mg/kg IV over 30 minutes (use ideal body weight). Maintenance: 0.5-0.7 mg/kg/hour IV infusion for non-smoking adults; 0.8-1.0 mg/kg/hour for smokers. Oral: 200-400 mg every 6-8 hours (extended-release formulations available).
Acetylcysteine 600 mg orally once daily, or 200 mg orally three times daily. Also available as 10% or 20% solution for inhalation: 3-5 m L of 20% solution or 6-10 m L of 10% solution nebulized three to four times daily.
Terminal elimination half-life is approximately 7-9 hours in healthy adults. In smokers, half-life decreases to 4-5 hours. In patients with hepatic cirrhosis, heart failure, or COPD, half-life may prolong to 20-30 hours.
Terminal elimination half-life: 8-12 hours (healthy adults), prolonged to 15-20 hours in hepatic impairment. Clinical context: Supports twice-daily dosing in most patients.
Primarily hepatic via CYP1A2, with minor contributions from CYP3A4, CYP2E1, and CYP2D6. Metabolism may be saturated, leading to nonlinear kinetics at therapeutic doses.
Ipratropium: minimally metabolized via hydrolysis and conjugation; Albuterol: primarily metabolized by catechol-O-methyltransferase (COMT) and sulfation.
Primarily hepatic metabolism (approximately 90%) to 1,3-dimethyluric acid and other metabolites; renal excretion of unchanged drug accounts for about 10-13% of the dose. Less than 1% is excreted via bile or feces.
Renal: 60-70% as unchanged drug; biliary/fecal: 20-30% as metabolites; <10% in feces as unchanged drug.
Approximately 40% bound, primarily to albumin. In neonates, protein binding is lower (about 30%).
85-90% bound to albumin.
Approximately 0.5 L/kg (range 0.3-0.7 L/kg). Higher in premature infants and neonates (0.6-0.9 L/kg). Vd corresponds to total body water; aminophylline distributes into extracellular and intracellular fluid.
0.8-1.2 L/kg (wide distribution into tissues, including lungs).
Oral immediate-release: nearly 100%. Oral sustained-release: 80-100% depending on formulation. Rectal: variable (80-100%). Intravenous: 100%.
Oral: 60-80% (first-pass metabolism reduces bioavailability).
No specific dose adjustment required for GFR >10 m L/min. For GFR <10 m L/min: reduce dose by 50% and monitor serum theophylline levels closely.
No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, consider reducing oral dose by 50% or extending interval due to accumulation of acetylcysteine metabolites.
Child-Pugh Class A: reduce dose by 50%. Child-Pugh Class B: reduce dose by 75%. Child-Pugh Class C: use alternative therapy or reduce dose by 80-90% with close monitoring.
No specific guidelines; use with caution in severe hepatic impairment (Child-Pugh C) due to potential increased exposure.
Loading dose: 5-6 mg/kg IV over 30 minutes. Maintenance IV infusion: age 1-6 months: 0.5 mg/kg/hour; 6-12 months: 0.6-0.7 mg/kg/hour; 1-9 years: 0.8-1.0 mg/kg/hour; >9 years: 0.5-0.7 mg/kg/hour. Oral: 5-6 mg/kg every 6 hours (immediate-release) or every 12 hours (extended-release).
Inhalation: Infants and children: 1-2 m L of 20% solution or 2-4 m L of 10% solution nebulized three to four times daily. Oral: Not typically recommended for chronic use; for acetaminophen overdose, weight-based dosing is used.
Lower initial doses recommended (e.g., 300-400 mg/day oral) with slower titration, as clearance is decreased. Monitor serum theophylline levels and adjust to achieve 5-15 mcg/m L.
No specific dose adjustment; monitor for adverse effects such as bronchospasm or nausea. Use with caution in elderly with renal impairment (refer to renal adjustment).
Theophylline has a narrow therapeutic index; serum levels must be monitored. Severe toxicity can occur at levels above 20 mcg/m L, including seizures, cardiac arrhythmias, and death. Use with caution as serious adverse effects may occur without warning.
No FDA boxed warning exists for this combination product.
Monitor serum theophylline levels; adjust dose accordingly,Risk of toxicity is increased in patients with hepatic impairment, congestive heart failure, cor pulmonale, and elderly patients,May exacerbate or induce peptic ulcer disease, seizures, and other cardiac arrhythmias,Concurrent use with other xanthines can increase toxicity,Smoking cessation decreases clearance and may require dose reduction
Paradoxical bronchospasm, cardiovascular effects (tachycardia, hypertension), worsening of narrow-angle glaucoma, urinary retention, hypokalemia, and immediate hypersensitivity reactions.
Hypersensitivity to theophylline or any component,Active seizure disorder unless adequately controlled with medications,Severe cardiac arrhythmias (e.g., ventricular tachycardia),Pregnancy (controversial; use only if clearly needed)
Hypersensitivity to ipratropium, albuterol, or atropine; history of anaphylaxis to soya lecithin or related food products; narrow-angle glaucoma; prostatic hyperplasia or bladder neck obstruction (relative).
Avoid excessive intake of caffeine-containing foods and beverages (coffee, tea, cola, chocolate) as they may potentiate stimulant effects and increase risk of toxicity. High-fat meals may slow absorption of extended-release formulations. No other significant food interactions.
High-fat meals can increase absorption of theophylline; take on an empty stomach or with light snack for consistent effect. Avoid large amounts of charcoal-broiled foods as they may decrease drug levels. Caffeine-containing foods and beverages (coffee, tea, cola, chocolate) can potentiate side effects such as nervousness, tremor, and insomnia. Charbroiled meats and cruciferous vegetables (broccoli, Brussels sprouts) may induce metabolism and reduce effectiveness. Grapefruit juice may increase theophylline levels; avoid concurrent use.
Pregnancy Category C. First trimester: No adequate human studies; animal studies show no teratogenicity at clinically relevant doses. Second and third trimesters: Potential risk of fetal tachycardia, jitteriness, and hypoglycemia due to maternal theophylline levels; no clear teratogenic signal. Close monitoring recommended.
No adequate human data; animal studies show no evidence of teratogenicity. However, use only if clearly needed during pregnancy, especially first trimester.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.6-0.7. Infant serum levels are typically subtherapeutic, but irritability, jitteriness, and feeding intolerance have been reported. Caution advised; monitor infant for adverse effects. Benefit-risk assessment required.
Not known if excreted in human breast milk. Caution advised; consider developmental benefits vs risks. M/P ratio not available.
Pregnancy increases theophylline clearance by 20-40% due to increased hepatic metabolism and renal blood flow. Monitor serum levels and adjust dose to maintain therapeutic range. Consider extended-release formulations for stable levels. Postpartum: clearance may decrease rapidly, requiring dose reduction.
No dose adjustment routinely recommended; however, increased clearance may require monitoring for therapeutic effect.
Aminophylline is a bronchodilator that contains theophylline and ethylenediamine. Use with caution in patients with peptic ulcer, hyperthyroidism, or seizure disorders. Monitor serum theophylline levels (therapeutic range 10-20 mcg/m L). Avoid use in patients with active peptic ulcer disease. Ethylenediamine component may cause allergic reactions in sensitive patients. Dose adjustment required in hepatic impairment, heart failure, or elderly. Tachyphylaxis may occur with prolonged use. Cigarette smoking increases clearance; monitor levels closely. Consider drug interactions with cimetidine, fluoroquinolones, and macrolides which decrease clearance.
Accurbron (theophylline) has a narrow therapeutic index; serum levels should be maintained between 5-15 mcg/m L. Hepatic metabolism is highly variable; monitor levels closely in patients with liver impairment, heart failure, or those on interacting drugs. Smoking induces metabolism, requiring higher doses. Use with caution in elderly and patients with seizure disorders or peptic ulcer disease. Do not crush or chew extended-release tablets.
Do not chew or crush extended-release tablets; swallow whole.,Avoid consuming large amounts of caffeine (coffee, tea, cola, chocolate) as it may increase side effects.,Report symptoms of toxicity such as nausea, vomiting, insomnia, rapid heartbeat, or seizures immediately.,Take this medication exactly as prescribed; do not change dose without consulting your doctor.,Inform your doctor if you have a history of seizures, ulcers, or liver disease.,Do not smoke or stop smoking without medical advice as it affects how this medication works.
Take exactly as prescribed; do not change dose without doctor approval.,Do not crush or chew sustained-release tablets.,Avoid excessive intake of caffeine (coffee, tea, cola, chocolate) as it may increase side effects like nausea, jitteriness, and insomnia.,Report any symptoms of toxicity: persistent nausea, vomiting, insomnia, rapid heartbeat, seizures.,Smoking or quitting smoking can affect theophylline levels; inform your doctor about any changes in smoking habits.,Keep regular appointments for blood tests to monitor drug levels.,Avoid taking other medications, including over-the-counter drugs and herbal supplements, without consulting your doctor.
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AMINOPHYLLINE DYE FREE vs ACCURBRON, answered by our medical review team.
AMINOPHYLLINE DYE FREE is a Xanthine Bronchodilator that works by Aminophylline is a salt form of theophylline that exerts bronchodilation by inhibiting phosphodiesterase, increasing intracellular c AMP. It also blocks adenosine receptors, stimulates central respiratory drive, and reduces diaphragmatic fatigue.. ACCURBRON is a Methylxanthine Bronchodilator that works by Ipratropium bromide is an anticholinergic agent that inhibits muscarinic acetylcholine receptors (M1-M3), reducing vagal tone and bronchoconstriction. Albuterol is a beta2-adrenergic agonist that stimulates adenylate cyclase, increasing c AMP and causing bronchodilation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AMINOPHYLLINE DYE FREE and ACCURBRON depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AMINOPHYLLINE DYE FREE is: Loading dose: 6 mg/kg IV over 30 minutes (use ideal body weight). Maintenance: 0.5-0.7 mg/kg/hour IV infusion for non-smoking adults; 0.8-1.0 mg/kg/hour for smokers. Oral: 200-400 mg every 6-8 hours (extended-release formulations available).. The standard adult dose of ACCURBRON is: Acetylcysteine 600 mg orally once daily, or 200 mg orally three times daily. Also available as 10% or 20% solution for inhalation: 3-5 m L of 20% solution or 6-10 m L of 10% solution nebulized three to four times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AMINOPHYLLINE DYE FREE and ACCURBRON in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AMINOPHYLLINE DYE FREE is classified as Category C. Pregnancy Category C. First trimester: No adequate human studies; animal studies show no teratogenicity at clinically relevant doses. Second and third trimesters: Potential risk of. ACCURBRON is classified as Category C. No adequate human data; animal studies show no evidence of teratogenicity. However, use only if clearly needed during pregnancy, especially first trimester.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.